-
Introduce two new gout drug projects, Tonghua Dongbao and WuXi AppTec have reached a cooperation
Time of Update: 2021-08-09
On June 30, Tonghua Dongbao announced that its subsidiary Dongbao Zixing and WuXi AppTec signed two Class 1 new drug technology transfer contracts for the treatment of gout (hyperuricemia), and obtained THDB130/THDB131 and THDB150/ THDB151 has the global intellectual property rights and related interests of the products of the two projects, and is responsible for the follow-up clinical development, production and commercialization activities of the products of this project according to the agreement between the two parties .
-
Targeting CCR4 "Moglizumab" submits a listing application in China
Time of Update: 2021-08-09
Public information shows that mogamulizumab is a CCR4 targeting antibody that has been approved by the FDA for breakthrough therapy and priority review, and has been approved for marketing in the United States for the treatment of mycosis fungoides ( MF) or Sezari syndrome (SS) in adult patients .
Retrieved August 8, 2018, from https:// -announces-fda-approval-of-poteligeo-mogamulizumab-kpkc-for-the-treatment-of-mycosis-fungoides-and-sezary-syndrome-300694118.
-
These pharmacies do not need to have licensed pharmacists
Time of Update: 2021-08-09
Specifically, for the above policy, for pharmaceutical retail companies that started before January 1, 2016, sells prescription drugs and Class A over-the-counter drugs, and have not yet equipped with a licensed pharmacist to review prescriptions, they can use other pharmacy technicians who have been qualified according to law to assume the duties of a licensed pharmacist.
-
Biopharmaceutical investment is seriously "involved" KRAS G12C hot targets are too crowded!
Time of Update: 2021-08-09
As long as biopharmaceutical talents have bold and reasonable innovative thinking, they can open up new fields for the needs of patients and develop original innovative drugs at low cost and high efficiency .
-
These pharmaceutical companies are leading the way with 50 billion large varieties
Time of Update: 2021-08-09
Layout of pharmaceutical companies getting togetherOn June 29, the website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) showed that China’s first original antibody-conjugated drug (ADC) new drug vedicitumumab ("Recombinant Injection" Humanized anti-HER2 monoclonal antibody-MMAE coupling agent") was officially included in the breakthrough therapy category, and the indications are HER2-positive advanced breast cancer patients with liver metastases who have been treated with trastuzumab and taxanes in the past .
-
Express Roche's PD-1/LAG-3 bispecific antibody applied for clinical application in China
Time of Update: 2021-08-09
Source: Guanlan PharmaceuticalThe Center for Drug Evaluation (CDE) of the China National Medical Products Administration showed that the RO7247669 injection being developed by Roche has been declared for clinical use in China and was accepted on July 2 .
-
Yuandong Bio: The application for clinical trial of biological drug EP-9001A injection was accepted
Time of Update: 2021-08-09
("Youluo Bio") has recently received the IND (New Drug) for EP-9001A injection issued by the State Food and Drug Administration.
-
What opportunities do the provincial medical insurance drug catalogs have for orderly cleaning up the removed drugs?
Time of Update: 2021-08-09
In accordance with the national top-level policy design, the medical insurance drug catalogs of all provinces must be cleaned up in an orderly manner: the drugs in the key monitoring catalogs are first removed from the medical insurance catalogs; in principle, the remaining local supplementary varieties will be cleared within three years, and the proportions of the three-year cleared varieties are 40%, 40%, and 40% respectively.
-
10 license in/out transactions for domestic pharmaceutical companies in June
Time of Update: 2021-08-09
Drug name: AdagrasibAuthorized party: Mirati TherapeuticsAuthorized party: Mirati TherapeuticsIntroducer: Zai LabIntroducer: Zai LabOn June 1, Zai Lab announced that it has reached a cooperation with Mirati Therapeutics (Mirati), and Zai Lab has obtained the right to develop and exclusively commercialize Adagrasib in Greater China (Mainland China, Hong Kong, Macau and Taiwan) .
-
The reimbursement of drugs added in 187 provinces stopped after one month after being transferred out of the medical insurance catalog
Time of Update: 2021-08-09
On June 30, the Jilin Provincial Medical Insurance Bureau and the Jilin Provincial Department of Human Resources and Social Security announced the "Notice on Doing a Good Job in the Province’s Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List for the Province’s Digestion of Drugs in 2021".
-
The average price of medicines is reduced by 56%
Time of Update: 2021-08-09
In the fifth batch of centralized drug procurement organized by countries, 11 products of 10 foreign pharmaceutical companies are planned to be selected, involving French Sanofi, American General Motors, German Fresenius, Israel Teva, etc.
-
The State Food and Drug Administration Terminates Huquan Pharmaceutical Industry Danggui Shaoyao Granules Chinese Medicine Variety Protection Early
Time of Update: 2021-08-09
and the opinions of the National Traditional Chinese Medicine Variety Protection Review Committee terminated early the protection of the Chinese medicine variety protection of Danggui Shaoyao Granules .
-
Hengrui has another big move!
Time of Update: 2021-08-09
Since the results of the fifth batch of national selections have just been finalized, and Hengrui’s contrast agent iodixanol injection regrets to be out of the game, some relevant people have analyzed Cyberlan and pointed out that Hengrui’s adjustment may be due to the loss of key products in the imaging field.
-
The vending machine can sell prescription drugs
Time of Update: 2021-08-09
A province issued a document that social pharmacies with Internet drug sales qualifications can sell prescription drugs through remote medicine cabinets (automatic medicine vending machines) .
This also means that social pharmacies with Internet drug sales qualifications can sell prescription drugs through remote medicine cabinets (automatic vending machines) .
-
CSPC Mabaloxavir's first generic drug was reported for listing, and the original research was approved in China in only 2 months
Time of Update: 2021-08-09
On April 29 this year, Roche's original drug Xofluza was just approved for import .
Mabaloxavir is a new anti-influenza drug, originally developed by Japanese pharmaceutical company Shiono Yoshihide .
Xofluza is a single-dose oral drug with a brand-new anti-influenza mechanism of action.
-
Targeting the GAS6-AXL pathway!
Time of Update: 2021-08-08
According to reports, this time approved in China is a randomized, double-blind, controlled, adaptive phase 3 clinical study, which aims to evaluate the effectiveness and safety of 3D229 combined with paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer.
-
LEO Pharma and X-Chem will cooperate in the development of new drugs for skin diseases
Time of Update: 2021-08-08
According to the agreement, X-Chem will use its proprietary DNA Encoded Compound Library (DEL) to screen multiple potential FIC (first-in-class) or BIC (best-in-class) targets for LEO Pharma.
-
Hengrui Medicine: Apatinib Mesylate Tablets Obtained Drug Clinical Trial Approval Notice
Time of Update: 2021-08-08
According to the "Drug Administration Law of the People's Republic of China" and related regulations, after review, the apatinib mesylate accepted on April 25, 2021 meets the relevant requirements of drug registration, and it is agreed to be used for gastric cancer or gastroesophageal junction cancer.
-
Submitted a domestic market application for nascentumumab in children with high-risk neuroblastoma
Time of Update: 2021-08-08
Naxitumumab is a relapsed/refractory high-risk neuroblastoma treatment drug developed by Y-mabs.
cn/v5/home/)With the two GD2 antibodies of Detuximab and Naxitumumab submitted for NDA in China, it is believed that patients with high-risk neuroblastoma will usher in new treatment options and obtain longer survival benefits .
-
The latest drug and device list approved worldwide in June
Time of Update: 2021-08-08
Table 5: Innovative medical devices approved for marketing in June 2021Source: National Medical Device Evaluation CenterAs of July 2, 2021, in June 2021, the State Administration has approved a total of 155 Class III medical device products for the first registration, of which 118 are domestically produced and 37 are imported .
